



**RPG LIFE SCIENCES LIMITED**  
Unit No. 208-213, B Wing,  
Bezzola Complex,  
Sion-Trombay Road, Chembur,  
Mumbai 400071, India  
Tel: +91-22-25292152-55  
Fax: +91-22-25297423

July 31, 2020

To,

The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, 5th Floor  
Plot No. C1, 'G' Block, Bandra-Kurla Complex  
Bandra (East), Mumbai 400 051.

BSE Limited  
Corporate Relationship Department Floor  
25, P.J. Towers  
Dalal Street  
Mumbai 400 001.

**Symbol: RPGLIFE**

**Scrip code: 532983**

Dear Sirs,

**Sub: Press Release - Financial Results**

Please find enclosed herewith a copy of press release with respect to Unaudited Financial Results of the Company for the quarter ended June 30, 2020.

Kindly take the above on record.

Thanking you,

Yours faithfully,  
For RPG Life Sciences Limited

Rajesh Shirambekar  
Head - Legal & Company Secretary



Encl: as above



**Quarter 1 PBT grew by 309% Q-o-Q and 18% Y-o-Y.  
Revenue from operations grows by 3% Q-o-Q.**

**Mumbai, 31<sup>st</sup> July, 2020:** RPG Life Sciences Limited has announced its financial results for the quarter ended 30<sup>th</sup> June 2020.

	<b>YoY Net Revenue from Operations</b>	<b>YoY PBT from Operations</b>
Q1 FY 21 Highlights	Rs 91.65 crores—down from Rs 94.04 crores	Rs 12.83 crores – up from Rs 10.86 crores

RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in profits by 18% Y-o-Y for Q1 FY 21. Revenue from Operations at Rs. 91.65 crores had a decline of -2.5%, however, EBITDA margins improved from 16.5% to 18.9% Y-o-Y.

Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “The overall performance of the Company in the first quarter of this fiscal has been satisfactory, particularly in view of unprecedented business environment due to Covid-19 pandemic. Despite a marginal drop in revenue y-o-y, the profits increased by 18%. Better product mix and opex control helped in improving the overall profitability. Domestic Formulations, the biggest contributor of our business, will continue to be our thrust area. The measures that contributed to our turnaround last year will continue to drive our operations and these are product portfolio augmentation, life cycle management of our ‘text book’ brand assets, sales force effectiveness, sales hygiene and opex control. In June 2020, we also commercialized generic version of a complex generic product, Prolonged Release Sodium Valproate formulation, for our UK customer after its successful approval by UK MHRA.”

**RPG Life Sciences Ltd ([www.rpglifesciences.com](http://www.rpglifesciences.com)):**

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical Company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The Company is a research-based pharmaceutical Company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

**RPG Enterprises ([www.rpggroup.com](http://www.rpggroup.com)):**

RPG Enterprises, established in 1979, is one of India’s fastest growing business Groups with a turnover of US\$ 4 Billion. The Group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Speciality as well as in emerging innovation-led technology businesses.

**Media Contact:**

**Sumeet Chatterjee**

**Senior Vice President – Group Communications**

**[sumeet@rpg.in](mailto:sumeet@rpg.in)**

**+91 9820340650**

